// App-Quantinova.ai

P4-22-06 : Treatment postprogression in women with endocrine-resistant HR+/HER2- advanced breast cancer who received palbociclib plus fulvestrant in PALOMA-3

Researchers

Presenter

  • NC Turner

Principal Investigators

  • F André

  • M Cristofanilli

  • S Verma

  • H Iwata

  • S Loi

  • N Harbeck

  • J Ro

  • M Colleoni

  • K Zhang

  • C Huang Bartlett

  • C Giorgetti

  • D Slamon

Medical Centers

  • Istituto Europeo di Oncologia, Milano, Italy

  • Institut Gustave-Roussy, Villejuif, France

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • Brustzentrum der Universitat Munchen (LMU), Munich, Germany

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • University of Calgary, Calgary, AB, Canada

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

Locations

  • Canada

  • Japan

  • Italy

  • Germany

  • United Kingdom

  • Australia

  • United States

  • France

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Breast cancer

  • Solid malignancies

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Capecitabine

  • Fulvestrant

  • Palbociclib

  • Exemestane

  • Paclitaxel

  • Mofezolac

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved